drugset / Trial / NCT00413686
Study to Assess Safety of AZD7762 Administered Alone and in Combination With Gemcitabine in Patients With Advanced Solid Malignancies
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is an open-label, multi-center, dose-escalation, Phase I study to evaluate the safety, tolerability, and pharmacokinetics and to investigate biomarker changes of AZD7762 administered as a single intravenous unit and in combination with gemcitabine. The study is sponsored by AstraZeneca.
Timeline
- Start
- 2006-12
- Primary completion
- 2010-05
- Completion
- 2010-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AZD7762 | Small molecule | — | Intravenous |
| Subject | Gemcitabine | Small molecule | — | Intravenous |